Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation
NCT05251129 · Montefiore Medical Center · NA · withdrawn · last registry update 2025-01-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study never submitted. Study team instead conducted a retrospective study which did not qualify for registration.” | – | Registry record, Montefiore Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HMGCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-13Results posted on the registry: Boehringer Ingelheim, Rosuvastatin + Digoxin (NCT05741372)
- 2026-01-09Results posted on the registry: Boehringer Ingelheim, Zongertinib + Dabigatran-etexilate (NCT06504862)
- 2025-12-31Phase 3 first posted: Beni-Suef University, rosuvastatin drug + Patients received rosuvastatin ezetimibe10/10mg (NCT07313124)
- 2025-12-23Results posted on the registry: The George Washington University Biostatistics Center, Pravastatin (NCT03944512)
- 2025-12-23Also stopped (terminated): The George Washington University Biostatistics Center, Pravastatin (NCT03944512)
- 2025-12-12Results posted on the registry: Eli Lilly and Company, Imlunestrant + Repaglinide (NCT05444556)
- 2025-12-05Results posted on the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Evobrutinib (45mg) + Digoxin (0.25mg) (NCT05064488)
- 2025-12-01Results posted on the registry: Columbia University, Low Dose Lovastatin + High Dose Lovastatin (NCT01976936)
- 2025-11-25Also stopped (terminated): Universitaire Ziekenhuizen KU Leuven, Rosuvastatin 10mg (NCT04883840)
- 2025-11-20Phase 3 first posted: Sohaib Ashraf, Bempedoic Acid 180 MG Oral Tablet + Rosuvastatin 5 mg (NCT07239414)
- 2025-11-18Phase 3 first posted: Duke University, Rosuvastatin 20 Mg Oral Tablet + Colchicine 0.5 MG Oral Tablet Once Daily (NCT07232069)
- 2025-10-14Phase 3 first posted: Merck Sharp & Dohme LLC, Enlicitide + Rosuvastatin (NCT07216482)
- 2025-09-16Results posted on the registry: Eli Lilly and Company, Rosuvastatin + Selpercatinib (NCT05906836)
- 2025-09-09Results posted on the registry: Organon and Co, Atozet 10/40 mg or 10/80 mg + Lipitor 40 mg or 80 mg (NCT05761444)
- 2025-08-22Results posted on the registry: University of Chicago, Atorvastatin (NCT02603328)
- 2025-07-16Results posted on the registry: Juan A. Arnaiz, Switch ritonavir-boosted PI + Continue Ritonavir-boosted PI+Rosuvastatin (NCT01935674)
- 2025-07-01Phase 3 first posted: Central South University, Atorvastatin + Metformin (NCT07045142)
- 2025-07-01Results posted on the registry: University College, London, Simvastatin (NCT03896217)
- 2025-06-10Phase 3 first posted: Aarhus University Hospital, acetylsalicyclic acid (ASA) + Clopidogrel (NCT07012629)
- 2025-05-29Results posted on the registry: Provident Clinical Research, Omacor + simvastatin (NCT00678743)
- 2025-05-23Results posted on the registry: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Cardiovascular Polypill + Treatment Prevention for Secondary CV (NCT02596126)
- 2025-05-16Phase 3 first posted: University of Colorado, Denver, Metformin + semaglutide (NCT06975111)
- 2025-05-15Phase 3 first posted: HealthBio, Inc., Maraviroc (MVC) + Atorvastatin, 10mg, 20mg, 40mg (NCT06974084)
- 2025-04-22Also stopped (withdrawn): ViiV Healthcare, Part A, C and D: VH3739937 500 mg + Part A: VH3739937 100 mg (NCT06533280)
- 2025-04-16Phase 3 first posted: Hospital do Coracao, Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg (NCT06930885)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision